Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah‐Eddin Al‐Batran, Alexander Reichart, Nils Homann et al.|The Lancet|2019Cited by 2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trialVolker Heinemann, Sebastian Stintzing, Ludwig Fischer von Weikersthal et al.|The Lancet Oncology|2014Cited by 1.7k
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal CancerSabine Tejpar, Volker Heinemann, Sebastian Stintzing et al.|JAMA Oncology|2016Cited by 722
The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trialsJulian Walter Holch, Volker Heinemann, Ingrid Ricard et al.|European Journal of Cancer|2016Cited by 533
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trialSebastian Stintzing, Volker Heinemann, Frank Kullmann et al.|The Lancet Oncology|2016Cited by 417